SCHEMBL3517951

SCHEMBL3517951

CN(C)C(=O)C1(c2ccccc2)CCCCC1CO

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 13/20 0.44
SLC6A4 P31645 11/20 0.44
OPRM1 P35372 2/20 0.44
SLC6A3 Q01959 6/20 0.43
CYP2D6 P10635 1/20 0.41
HTR2C P28335 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MAPK1 P28482 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
SIGMAR1 Q99720 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18033725 1.00 SLC6A2 (0.44) SLC6A2SLC6A4OPRM1SLC6A3CYP2D6
SCHEMBL8241681 1.00 SLC6A2 (0.44) SLC6A2SLC6A4OPRM1SLC6A3CYP2D6
SCHEMBL19772415 1.00 SLC6A2 (0.44) SLC6A2SLC6A4OPRM1SLC6A3CYP2D6
Dimethylformamide SCHEMBL28775279 0.83 SLC6A2 (0.41) SLC6A2SLC6A4OPRM1SLC6A3CYP2D6
SCHEMBL3520503 0.81 SLC6A4 (0.61) SLC6A2SLC6A4SLC6A3
SCHEMBL18752266 0.75 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
SCHEMBL28838197 0.74 AKR1C1 (0.45) SLC6A2SLC6A4OPRM1SLC6A3CYP2D6
SCHEMBL13253823 0.72 SLC6A4 (0.67) SLC6A2SLC6A4OPRM1SLC6A3OPRD1
SCHEMBL3517810 0.72 SLC6A4 (0.67) SLC6A2SLC6A4OPRM1SLC6A3OPRD1
SCHEMBL19772409 0.72 SLC6A4 (0.67) SLC6A2SLC6A4OPRM1SLC6A3OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10562878-B2 Cycloalkylamines as monoamine reuptake inhibitors SUNOVION PHARAMCEUTICALS INC. (US) 2020-02-18 US disclosed
US-9868718-B2 Cycloalkylamines as monoamine reuptake inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2018-01-16 US disclosed
EP-1976513-B1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SUNOVION PHARMACEUTICALS INC (US) 2016-08-24 EP disclosed
US-20150126511-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SUNOVION PHARMACEUTICALS INC. 2015-05-07 US disclosed
US-8877975-B2 Cycloalkylamines as monoamine reuptake inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2014-11-04 US disclosed
US-20100190861-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SUNOVION PHARMACEUTICALS INC. 2010-07-29 US disclosed
US-20070203111-A1 Cycloalkylamines as monoamine reuptake inhibitors SEPRACOR INC. (US) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150126511-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 SLC6A2 2/4885SLC6A4 5/4885OPRM1 185/4885
US-20070203111-A1 Cycloalkylamines as monoamine reuptake inhibitors SLC18A2, SLC6A2, SLC18A3 SLC6A2 2/4885SLC6A4 5/4885OPRM1 185/4885
US-20100190861-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 SLC6A2 2/4885SLC6A4 5/4885OPRM1 185/4885
US-10562878-B2 Cycloalkylamines as monoamine reuptake inhibitors SLC18A2, SLC6A2, SLC18A3 SLC6A2 2/4885SLC6A4 5/4885OPRM1 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.